Anavex Life Sciences Corp.

AI-generated fair value estimate for this company.

Method: Risk-adjusted NPV (rNPV) of lead pipeline asset plus net cash, since this is a pre-revenue clinical-stage biotech: ~$1.5B estimated global peak sales for oral blarcamesine in early Alzheimer's disease (differentiated as an oral small-molecule sigma-1 agonist vs. IV anti-amyloid antibodies); 35% commercial operating margin ($525M peak annual pre-risk cash flow); 25% probability of success reflecting completed Phase 2b/3 data but not-yet-aligned FDA regulatory pathway (per the company's own November 2025 regulatory update); launch assumed in year 3, ramping to full peak by year 6, sustained years 6-10 with no terminal value after exclusivity; 11% discount rate; $118.33M net cash added unrisked; 92.70 million shares outstanding.

Reasoning: Anavex has no product revenue, so a standard FCF DCF does not apply; a probability-weighted NPV of its lead Alzheimer's asset plus net cash is the standard biotech-appropriate method, and the discounted probability of success reflects real, disclosed regulatory-alignment uncertainty with the FDA even though pivotal-stage trials are complete.